Lotta Särkilahti, Camilla Isaksson, Tomi S Mikkola
{"title":"Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Bulking Agent for Stress Urinary Incontinence: Patient Choice and Outcomes in Finland.","authors":"Lotta Särkilahti, Camilla Isaksson, Tomi S Mikkola","doi":"10.1007/s00192-025-06119-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>Since 2018 we have offered polyacrylamide hydrogel (PAHG) injection as an alternative to tension-free vaginal tape (TVT) for primary stress urinary incontinence (SUI). Our study aim was to investigate patient choice, demographics, re-treatments, and complications for these procedures.</p><p><strong>Methods: </strong>Patient demographics were collected from the Hospital Registry for women with primary SUI treated with TVT or PAHG, including patient age, body mass index, smoking status, obstetric history, and prior pelvic surgeries. Re-treatments and complications were collected at 2-year follow-up after each primary procedure.</p><p><strong>Results: </strong>Among 391 primary procedures, 55% (n = 217) of women chose the TVT and 45% (n = 174) the PAHG treatment, with similar patient demographics. Within 2 years, the re-treatment rates were 0.9% (n = 2) for TVT and 27.0% (n = 47) for PAHG (p < 0.001). Among patients undergoing re-treatment after primary PAHG, 57.4% (n = 27) opted for re-injection and 42.6% (n = 20) chose a mid-urethral sling. Three patients received TVT after two PAHG injection treatments. Complications occurred in 14.3% and 9.2% after TVT and PAHG respectively (p = 0.124). Complications after TVT ranged from Clavien-Dindo grades I-IIIb, with 4.1% of patients requiring reoperations, whereas PAHG complications were grades I-II with no reoperations. Including re-treatments, complication rates were 14.3% (TVT) and 10.9% (PAHG; p = 0.322).</p><p><strong>Conclusions: </strong>Similar clinical profiles in both TVT and PAHG groups suggest no specific demographic factors predict decision making. After a 2-year follow-up, the overall complication rates were similar, with PAHG associated with a higher likelihood of requiring re-treatment, whereas TVT carried a greater risk of severe complications. The re-treatment rates were lower than previously reported, indicating that actual patients are fairly satisfied with their primary choice.</p>","PeriodicalId":14355,"journal":{"name":"International Urogynecology Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urogynecology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00192-025-06119-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and hypothesis: Since 2018 we have offered polyacrylamide hydrogel (PAHG) injection as an alternative to tension-free vaginal tape (TVT) for primary stress urinary incontinence (SUI). Our study aim was to investigate patient choice, demographics, re-treatments, and complications for these procedures.
Methods: Patient demographics were collected from the Hospital Registry for women with primary SUI treated with TVT or PAHG, including patient age, body mass index, smoking status, obstetric history, and prior pelvic surgeries. Re-treatments and complications were collected at 2-year follow-up after each primary procedure.
Results: Among 391 primary procedures, 55% (n = 217) of women chose the TVT and 45% (n = 174) the PAHG treatment, with similar patient demographics. Within 2 years, the re-treatment rates were 0.9% (n = 2) for TVT and 27.0% (n = 47) for PAHG (p < 0.001). Among patients undergoing re-treatment after primary PAHG, 57.4% (n = 27) opted for re-injection and 42.6% (n = 20) chose a mid-urethral sling. Three patients received TVT after two PAHG injection treatments. Complications occurred in 14.3% and 9.2% after TVT and PAHG respectively (p = 0.124). Complications after TVT ranged from Clavien-Dindo grades I-IIIb, with 4.1% of patients requiring reoperations, whereas PAHG complications were grades I-II with no reoperations. Including re-treatments, complication rates were 14.3% (TVT) and 10.9% (PAHG; p = 0.322).
Conclusions: Similar clinical profiles in both TVT and PAHG groups suggest no specific demographic factors predict decision making. After a 2-year follow-up, the overall complication rates were similar, with PAHG associated with a higher likelihood of requiring re-treatment, whereas TVT carried a greater risk of severe complications. The re-treatment rates were lower than previously reported, indicating that actual patients are fairly satisfied with their primary choice.
期刊介绍:
The International Urogynecology Journal is the official journal of the International Urogynecological Association (IUGA).The International Urogynecology Journal has evolved in response to a perceived need amongst the clinicians, scientists, and researchers active in the field of urogynecology and pelvic floor disorders. Gynecologists, urologists, physiotherapists, nurses and basic scientists require regular means of communication within this field of pelvic floor dysfunction to express new ideas and research, and to review clinical practice in the diagnosis and treatment of women with disorders of the pelvic floor. This Journal has adopted the peer review process for all original contributions and will maintain high standards with regard to the research published therein. The clinical approach to urogynecology and pelvic floor disorders will be emphasized with each issue containing clinically relevant material that will be immediately applicable for clinical medicine. This publication covers all aspects of the field in an interdisciplinary fashion